Breaking News

Macquarie-Led Group to Buy Louisiana Utility Cleco for $3.4 Billion
Tweet TWEET

RBCC Retains New IR Group to Optimize Investor Outreach, Relay Key Growth Plans

  RBCC Retains New IR Group to Optimize Investor Outreach, Relay Key Growth   Plans  Business Wire  NOKOMIS, Fla. -- February 13, 2013  Rainbow Coral Corp. (OTCBB: RBCC) is kicking-off a new investor outreach campaign by hiring an up-and-coming, dynamic investor relations group committed to enhancing the visibility and reach of RBCC’s strategic growth initiatives.  “Our new investor relations partners have the hands-on expertise and industry relevance we need to thoroughly communicate our corporate plans and activities to current and potential investors as timely and efficiently as possible,” said RBCC CEO Patrick Brown. “We’re confident that 2013 is shaping up to be an incredible year for RBCC, and we want to make sure that it doesn’t go unnoticed.”  RBCC’s biotech division, Rainbow BioSciences, maintains high interest in the Bio-Assembler, a biotech device owned by RBCC partner Nano3D BioSciences. This new technology enables scientists to grow cells in a three-dimensional environment using nanoparticles that produce magnetic fields to lift cells from the bottom of petri dishes.  These 3D cultures form tissues that more closely resemble those found in the human body, as compared to conventional cell cultures grown on flat surfaces. This valuable technique has the potential to drastically reduce the cost of developing new drugs as well as eliminate the use of animals when testing the safety of manufactured chemicals. Additionally, the Bio-Assembler has the profound potential to grow functional organs from scratch.  RBCC is closely working with Nano3D to further develop and market the Bio-Assembler worldwide – and by retaining an adept investor relations group, RBCC is laying the foundation for an efficiently executed and far-reaching growth strategy.  For more information on Rainbow BioSciences, please visitwww.rainbowbiosciences.com/investors.html.  Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN).  About Rainbow BioSciences  Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO info@rainbowcoral.com  
Press spacebar to pause and continue. Press esc to stop.